LifeSci Capital initiated coverage of Praxis Precision (PRAX) with an Outperform rating and $117 price target
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PRAX:
- Promising Outlook for Praxis Precision Medicines: Buy Rating Affirmed on Strong Drug Efficacy and Financial Position
- Praxis Precision price target raised to $65 from $61 at Jefferies
- Praxis Precision Medicines’ Positive Earnings Call Highlights Vormatrigine Success
- Praxis Precision price target raised to $115 from $105 at H.C. Wainwright
- Praxis Precision Medicines Reports Promising Study Results